NeuBase Therapeutics Inc (NAS:NBSE)
$ 0.378 -0.012499 (-3.2%) Market Cap: 1.42 Mil Enterprise Value: -5.82 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 21/100

NeuBase Therapeutics Inc Industry Updates Friday Transcript

Oct 06, 2020 / NTS GMT
Release Date Price: $155.8 (+0.52%)
Allison Formal
Myotonic Dystrophy Foundation - Moderator

I hope you've been enjoying the first day of MDF's first virtual conference. I'm Allison Formal, the senior science advisor at MDF. Welcome to this special time in our annual conference when our industry partners come together to share updates about their myotonic dystrophy programs in their cutting edge work in the development of different therapeutics.

This is a chance for us to hear directly from our partners about their approach, their process, and their progress. Today, we will hear from Avidity Biosciences; Ionis Pharmaceuticals; Dyne Therapeutics; and NeuBase. (Operator Instructions) Thank you so much for attending the conference. We hope you have a wonderful rest of the meeting. Thank you.

Art Levin
Avidity Biosciences, Inc. - Chief Scientific Officer

I'd like to thank the organizers for inviting me here today. My name is Art Levin, and I'm the Chief Scientific Officer at Avidity Biosciences. I'd like to talk to you today about antibody oligonucleotide conjugates for the treatment of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot